A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Subjects With Treatment Resistant Depression
Phase of Trial: Phase II
Latest Information Update: 10 Apr 2018
At a glance
- Drugs Esketamine (Primary)
- Indications Depression
- Focus Therapeutic Use
- Sponsors Janssen Pharmaceutical KK
- 05 Apr 2018 Planned End Date changed from 30 Jun 2019 to 10 Jun 2019.
- 21 Nov 2016 Status changed from not yet recruiting to recruiting.
- 11 Nov 2016 Planned initiation date changed from 1 Oct 2016 to 1 Nov 2016.